MedTrace Logo

Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis

NCT04413942 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2022-04-04

No results posted yet for this study

Summary

The study aims to evaluate the efficacy, improvement from baseline in Eczema Area and Severity Index (EASI) score, of multiple intravenous (IV) doses of FB825 in subjects with atopic dermatitis

Conditions

Interventions

BIOLOGICAL

FB825

Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE

OTHER

Placebo

Formulation buffer

Sponsors & Collaborators

  • Oneness Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • NienYi Chen, PhD · Oneness Biotech

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-10
Primary Completion
2021-12-31
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04413942 on ClinicalTrials.gov